{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:29:57Z","timestamp":1790792997572,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"1","funder":[{"name":"Psioxus Therapeutics Limited","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0510-7","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T06:02:47Z","timestamp":1548655367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)"],"prefix":"10.1136","volume":"7","author":[{"given":"Jean-Pascal","family":"Machiels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Geboes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wilkinson-Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Pover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Alvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Champion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"McElwaine-Johnn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Beadle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"issue":"3","key":"510_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006190","volume":"13","author":"R Cattaneo","year":"2017","unstructured":"Cattaneo R, Russell SJ. How to develop viruses into anticancer weapons. PLoS Pathog. 2017;13(3):e1006190.","journal-title":"PLoS Pathog"},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ctrv.2017.01.008","volume":"54","author":"J Martin-Liberal","year":"2017","unstructured":"Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev. 2017;54:74\u201386.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"510_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658\u201370.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"510_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/bjc.2015.481","volume":"114","author":"LW Seymour","year":"2016","unstructured":"Seymour LW, Fisher KD. Oncolytic viruses: finally delivering. Br J Cancer. 2016;114(4):357\u201361.","journal-title":"Br J Cancer"},{"issue":"8","key":"510_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559\u201367.","journal-title":"Nat Rev Cancer"},{"key":"510_CR6","doi-asserted-by":"crossref","unstructured":"Russell SJ, Peng KW. Oncolytic Virotherapy: a contest between apples and oranges. Mol Ther. 2017.","DOI":"10.1016\/j.ymthe.2017.03.026"},{"key":"510_CR7","doi-asserted-by":"crossref","unstructured":"Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2016;3(6):841\u20139.","DOI":"10.1001\/jamaoncol.2016.2064"},{"key":"510_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/805629","volume":"2012","author":"MS Ferguson","year":"2012","unstructured":"Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629.","journal-title":"Adv Virol"},{"key":"510_CR9","unstructured":"European Medicines Agency: Imlygic EPAR Product Information. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002771\/WC500201079.pdf . Accessed 27 July 2017."},{"key":"510_CR10","unstructured":"Food and Drug Administration: US prescribing information. IMLYGIC (talimogene laherparepvec). 2015. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM469575.pdf . Accessed 27 Jul 2017."},{"issue":"22","key":"510_CR11","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619\u201326.","journal-title":"J Clin Oncol"},{"issue":"6","key":"510_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008;3(6):e2409.","journal-title":"PLoS One"},{"key":"510_CR13","doi-asserted-by":"crossref","unstructured":"Dyer A, Ying D, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, Jager D. Oncolytic group B adenovirus enadenotucirev mediates non-apoptotic cell death with membrane permeabilisation and release of inflammatory mediators. Mol Ther Oncolytics. 2017.","DOI":"10.1016\/j.omto.2016.11.003"},{"issue":"5","key":"510_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177810","volume":"12","author":"N Marino","year":"2017","unstructured":"Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, Fisher KD, Champion BR, Brown ACN. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS One. 2017;12(5):e0177810.","journal-title":"PLoS One"},{"issue":"1","key":"510_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","volume":"5","author":"R Garcia-Carbonero","year":"2017","unstructured":"Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5(1):71.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"510_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/gt.2014.2","volume":"21","author":"Y Di","year":"2014","unstructured":"Di Y, Seymour L, Fisher K. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther. 2014;21(4):440\u20133.","journal-title":"Gene Ther"},{"key":"510_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","volume":"5","author":"S Illingworth","year":"2017","unstructured":"Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, et al. Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus. Mol Ther Oncolytics. 2017;5:62\u201374.","journal-title":"Mol Ther Oncolytics"},{"issue":"15","key":"510_CR18","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77(15):8263\u201371.","journal-title":"J Virol"},{"issue":"23","key":"510_CR19","doi-asserted-by":"publisher","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","volume":"78","author":"L Holterman","year":"2004","unstructured":"Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol. 2004;78(23):13207\u201315.","journal-title":"J Virol"},{"issue":"1","key":"510_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","volume":"14","author":"EJ Small","year":"2006","unstructured":"Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14(1):107\u201317.","journal-title":"Mol Ther"},{"issue":"4","key":"510_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/mt.2015.233","volume":"24","author":"A Tedcastle","year":"2016","unstructured":"Tedcastle A, Illingworth S, Brown A, Seymour LW, Fisher KD. Actin-resistant DNAse I expression from oncolytic adenovirus enadenotucirev enhances its intratumoral spread and reduces tumor growth. Mol Ther. 2016;24(4):796\u2013804.","journal-title":"Mol Ther"},{"issue":"8","key":"510_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.15252\/emmm.201707567","volume":"9","author":"JD Freedman","year":"2017","unstructured":"Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017;9(8):1067\u201387.","journal-title":"EMBO Mol Med"},{"issue":"4","key":"510_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"510_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109\u201319 e1110.","journal-title":"Cell"},{"key":"510_CR25","doi-asserted-by":"crossref","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127\u201337.","DOI":"10.1126\/scitranslmed.3003689"},{"issue":"4","key":"510_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307\u201314.","journal-title":"Cancer Immunol Immunother"},{"key":"510_CR27","unstructured":"Phase I study of enadenotucirev and PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors (SPICE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02636036 . Accessed 13 Nov 2017."},{"issue":"45","key":"510_CR28","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1038\/onc.2010.335","volume":"29","author":"CK Ingemarsdotter","year":"2010","unstructured":"Ingemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene. 2010;29(45):6051\u201363.","journal-title":"Oncogene"},{"key":"510_CR29","unstructured":"Phase I \/ Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients (OCTAVE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02028117 . Accessed 13 Nov 2017."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:51Z","timestamp":1601041491000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0510-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0510-7","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"31 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of each participating center and was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation of Good Clinical Practice guidelines. All patients provided written informed consent before study entry.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J-PM, RS, SR, ID, LD, and KG have no potential conflicts of interest to declare.CW-B and GP were employees of PsiOxus Therapeutics Limited at the time of the study.SA, BC, KF, and HM-J are employees of PsiOxus Therapeutics Limited.JB is an employee, company director, and shareholder of PsiOxus Therapeutics Limited.EC is a paid employee of START Madrid and HM Hospitales Group and is president and founder of Foundation INTHEOS. EC has stock and\/or ownership interests in START Madrid, OncoArt Associated and International Cancer Consultants and has received honoraria from HM Hospitales Group and travel\/accommodation expenses from Roche\/Genentech. EC has received research-related funding from AstraZeneca, Novartis, BeiGene and START Madrid. EC has received consulting and\/or advisory fees from Abbvie, Amcure, AstraZeneca, Celgene, EUSA Pharma, GLG, Guidepoint Global, Janssen-Cilag, Nanobiotix, Novartis, Pfizer, PsiOxus Therapeutics Limited, Roche\/Genentech, Seattle Genetics, SERVIER, and START Madrid.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"20"}}